bluuebunny/crossref_metadata_2025 huggingface dataset:
Change in T lymphocyte from Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma
Authors: Curry William T. , Gorrepati Ramana , Piesche Matthias , Sasada Tetsuro , Agarwalla Pankaj , Jones Pamela S. , Gerstner Elizabeth R. , Golby Alexandra J. , Batchelor Tracy T. , Wen Patrick Y. , Mihm Martin C. , Dranoff Glenn
Published: April 2023

Greatest percent change in expression of selected CD4+ and CD8+ T-lymphocyte markers of activation and regulation. * denotes statistical significance (P< 0.05).
Supplemental Figure S5 from The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment
Authors: Meisen W. Hans , Wohleb Eric S. , Jaime-Ramirez Alena Cristina , Bolyard Chelsea , Yoo Ji Young , Russell Luke , Hardcastle Jayson , Dubin Samuel , Muili Kamaldeen , Yu Jianhua , Caligiuri Michael , Godbout Jonathan , Kaur Balveen
Published: April 2023

Supplemental Figure S5. Murine TNFα reduces viral replication in infected human glioma cells.
Supplemental Figure S4 from The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment
Authors: Meisen W. Hans , Wohleb Eric S. , Jaime-Ramirez Alena Cristina , Bolyard Chelsea , Yoo Ji Young , Russell Luke , Hardcastle Jayson , Dubin Samuel , Muili Kamaldeen , Yu Jianhua , Caligiuri Michael , Godbout Jonathan , Kaur Balveen
Published: April 2023

Supplemental Figure S4. oHSV treatment increases secreted TNFα.
Supplemental Figure S3 from The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment
Authors: Meisen W. Hans , Wohleb Eric S. , Jaime-Ramirez Alena Cristina , Bolyard Chelsea , Yoo Ji Young , Russell Luke , Hardcastle Jayson , Dubin Samuel , Muili Kamaldeen , Yu Jianhua , Caligiuri Michael , Godbout Jonathan , Kaur Balveen
Published: April 2023

Supplemental Figure S3. Representative fluorescent images of uninfected and infected co-cultures 12 hours post infection.
Supplemental Figure S2 from The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment
Authors: Meisen W. Hans , Wohleb Eric S. , Jaime-Ramirez Alena Cristina , Bolyard Chelsea , Yoo Ji Young , Russell Luke , Hardcastle Jayson , Dubin Samuel , Muili Kamaldeen , Yu Jianhua , Caligiuri Michael , Godbout Jonathan , Kaur Balveen
Published: April 2023

Supplemental Figure S2. Species specificity of murine TNFα ELISA kit for murine and not human TNFα
Supplemental Figure Legends from The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment
Authors: Meisen W. Hans , Wohleb Eric S. , Jaime-Ramirez Alena Cristina , Bolyard Chelsea , Yoo Ji Young , Russell Luke , Hardcastle Jayson , Dubin Samuel , Muili Kamaldeen , Yu Jianhua , Caligiuri Michael , Godbout Jonathan , Kaur Balveen
Published: April 2023

Supplemental Figure Legends from The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment
Supplementary Tables S1-S3 from Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors
Authors: Tomlinson Benjamin K. , Thomson James A. , Bomalaski John S. , Diaz Monica , Akande Taiwo , Mahaffey Nichole , Li Tianhong , Dutia Mrinal P. , Kelly Karen , Gong I-Yeh , Semrad Thomas , Gandara David R. , Pan Chong-Xian , Lara Primo N.
Published: April 2023

Supplementary Tables S1-S3. Table S1: The complete dose escalation schema for ADI-PEG 20 in combination with docetaxel. Table S2: Details the completed pharmacodynamic data for individual patients. Includes concentrations of arginine and citrulline over time and the titers of antibodies to ADI-PEG 20. Table S3: Highlights response against tumor type in patients where response was able to be assessed.
Appendix from Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Authors: Montgomery Bruce , Eisenberger Mario A. , Rettig Matthew B. , Chu Franklin , Pili Roberto , Stephenson Joseph J. , Vogelzang Nicholas J. , Koletsky Alan J. , Nordquist Luke T. , Edenfield William J. , Mamlouk Khalid , Ferrante Karen J. , Taplin Mary-Ellen
Published: April 2023

Appendix
Supplemental Materials and Legend from Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
Authors: Keck Michaela K. , Zuo Zhixiang , Khattri Arun , Stricker Thomas P. , Brown Christopher D. , Imanguli Matin , Rieke Damian , Endhardt Katharina , Fang Petra , Brägelmann Johannes , DeBoer Rebecca , El-Dinali Mohamed , Aktolga Serdal , Lei Zhengdeng , Tan Patrick , Rozen Steve G. , Salgia Ravi , Weichselbaum Ralph R. , Lingen Mark W. , Story Michael D. , Ang K. Kian , Cohen Ezra E.W. , White Kevin P. , Vokes Everett E. , Seiwert Tanguy Y.
Published: April 2023

Supplemental Materials and Legend. Supplemental Experimental Procedures: Determination of HPV status; Gene expression profiling; Copy number aberration (CNA) experiment; Copy number aberration (CNA) analysis; Published Data Set Collection and Integration; Unsupervised Discovery of Gene Expression-Based Subtypes and Derivation of Gene Signatures; Validation of HNSCC Classification; Single Sample Gene Set Enrichment Analysis (ssGSEA); Pathway Analysis; Survival Analysis; Immunohistochemistry and Immunofluorescence. Supplementary Figure Legends. Supplementary Table S1. Data set source and group allocation Supplementary Table S3. Significant copy number gain and loss in the discovery set (101 samples and 75 genes). Supplementary Table S4. Significant copy number gain and loss in the validation set (55 samples and 72 genes) Supplementary Table S5. Significant copy number alterations per subtype.
Supplementary Tables S1-4 from Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer
Authors: Yang Yijun , Jia Dingwu , Kim Hogyoung , Abd Elmageed Zakaria Y. , Datta Amrita , Davis Rodney , Srivastav Sudesh , Moroz Krzysztof , Crawford Byron E. , Moparty Krishnarao , Thomas Raju , Hudson Robert S. , Ambs Stefan , Abdel-Mageed Asim B.
Published: April 2023

Table S1. TMA-4 patient characteristics. Table S2. qPCR primers. Table S3. miRNA primers. Table S4. EMSA oligonucleotides
Supplementary Figure S2 from Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer
Authors: Yang Yijun , Jia Dingwu , Kim Hogyoung , Abd Elmageed Zakaria Y. , Datta Amrita , Davis Rodney , Srivastav Sudesh , Moroz Krzysztof , Crawford Byron E. , Moparty Krishnarao , Thomas Raju , Hudson Robert S. , Ambs Stefan , Abdel-Mageed Asim B.
Published: April 2023

Suppressive subtractive hybridization and construction of race-based prostate tumor specific cDNA libraries
Supplementary Figure Legends from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
Authors: Hobor Sebastijan , Van Emburgh Beth O. , Crowley Emily , Misale Sandra , Di Nicolantonio Federica , Bardelli Alberto
Published: April 2023

PDF file - 105K
Supplementary Figure 4 from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
Authors: Hobor Sebastijan , Van Emburgh Beth O. , Crowley Emily , Misale Sandra , Di Nicolantonio Federica , Bardelli Alberto
Published: April 2023

PDF file - 118K, LIM1215 knocked-in with a KRAS G12R mutation are also capable of paracrine protection of sensitive wild type (wt) cells and secrete higher levels of TGFalpha.
Supplementary Figure 1 from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
Authors: Hobor Sebastijan , Van Emburgh Beth O. , Crowley Emily , Misale Sandra , Di Nicolantonio Federica , Bardelli Alberto
Published: April 2023

PDF file - 95K, Schematic representation of conditioned medium assay (CMA).
Supplemental Figure S1 from Nicotine Reduces Survival via Augmentation of Paracrine HGF–MET Signaling in the Pancreatic Cancer Microenvironment
Authors: Delitto Daniel , Zhang Dongyu , Han Song , Black Brian S. , Knowlton Andrea E. , Vlada Adrian C. , Sarosi George A. , Behrns Kevin E. , Thomas Ryan M. , Lu Xiaomin , Liu Chen , George Thomas J. , Hughes Steven J. , Wallet Shannon M. , Trevino Jose G.
Published: April 2023

Supplemental Figure S1. Induction of c-Met by nicotine occurs at the post-transcriptional level.
Supplementary Methods, Results and Tables from Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer
Authors: Callari Maurizio , Cappelletti Vera , D'Aiuto Francesca , Musella Valeria , Lembo Antonio , Petel Fabien , Karn Thomas , Iwamoto Takayuki , Provero Paolo , Daidone Maria Grazia , Gianni Luca , Bianchini Giampaolo
Published: April 2023

Table S1: Clinico-pathological features for samples in the PROGNOSTIC collection; Table S2: Clinico-pathological features for samples in the TAM collection; Table S3: Clinico-pathological features for samples in the CHEMO collection; Table S4: Output of immune cluster refinement in ER-HER2- samples. Five years DMFS for high, intermediate and low expression groups and log-rank test p-values (average and standard deviation of 100 10-fold cross-validations) are reported as a function of the number of genes; Table S5: Output of immune cluster refinement in HER2+ samples. Five years DMFS for high, intermediate and low expression groups and log-rank test p-values (average and standard deviation of 100 10-fold cross-validations) are reported as a function of the number of genes; Table S6: Output of proliferation cluster refinement in 508 ER+HER2- samples. Five-years DMFS for high, intermediate and low expression groups and log-rank test p-values (average and standard deviation of 100 10-fold cross-validations) are reported as a function of the number of genes; Table S7: Output of ER-related cluster refinement in 394 high proliferation ER+HER2- samples. Five-years DMFS for high, intermediate and low expression groups and log-rank test p-values (average and standard deviation of 100 10-fold cross-validations) are reported as a function of the number of genes; Table S8: Univariable Cox regression analysis for the CTM in the combined dataset or in each dataset for ER- or HER2+ cases or separately for ER-HER2- and HER2+ subgroups; Table S9: Univariable and multivariable Cox regression analysis in 205 ER-HER2- and HER2+ samples from the CHEMO collection (all biomarkers were used as continous variables); Table S10: Univariable Cox regression analysis for the combined proliferation and ER-related metagenes in ER+HER2- cases from the combined dataset or from each dataset;
supplemental tables 1-5 and figure legends from Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Authors: Wilson Melissa A. , Zhao Fengmin , Khare Sanika , Roszik Jason , Woodman Scott E. , D'Andrea Kurt , Wubbenhorst Bradley , Rimm David L. , Kirkwood John M. , Kluger Harriet M. , Schuchter Lynn M. , Lee Sandra J. , Flaherty Keith T. , Nathanson Katherine L.
Published: April 2023

Supplemental Table 1: Genes analyzed which are known to be involved in melanoma pathogenesis Supplemental Table 2: Patient demographics and disease characteristics Supplemental Table 3: Clinical outcomes Supplemental Table 4: BRAF gene amplification is associated with BRAF somatic mutations Supplemental Table 5: RAF1 gene amplification is associated with worse PS Supplemental Figure Legends
Supplement Figure 3 from Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Authors: Wilson Melissa A. , Zhao Fengmin , Khare Sanika , Roszik Jason , Woodman Scott E. , D'Andrea Kurt , Wubbenhorst Bradley , Rimm David L. , Kirkwood John M. , Kluger Harriet M. , Schuchter Lynn M. , Lee Sandra J. , Flaherty Keith T. , Nathanson Katherine L.
Published: April 2023

Supplemental Figure 3. BRAF and MET gene amplifications are associated with BRAF V600K mutation cohort
Supplement Figure 2 from Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Authors: Wilson Melissa A. , Zhao Fengmin , Khare Sanika , Roszik Jason , Woodman Scott E. , D'Andrea Kurt , Wubbenhorst Bradley , Rimm David L. , Kirkwood John M. , Kluger Harriet M. , Schuchter Lynn M. , Lee Sandra J. , Flaherty Keith T. , Nathanson Katherine L.
Published: April 2023

Supplemental Figure 2. Kaplan-Meier curves demonstrating no association between RAF1 amplification and NRAS somatic mutations on PFS or OS
Supplement Figure 1 from Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Authors: Wilson Melissa A. , Zhao Fengmin , Khare Sanika , Roszik Jason , Woodman Scott E. , D'Andrea Kurt , Wubbenhorst Bradley , Rimm David L. , Kirkwood John M. , Kluger Harriet M. , Schuchter Lynn M. , Lee Sandra J. , Flaherty Keith T. , Nathanson Katherine L.
Published: April 2023

Supplemental Figure 1. Frequency plot of copy gains and losses in somatic mutation cohorts across the whole genome.
Supplemental Methods, Table 1 and Figures 1-2 from Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients
Authors: Xu Xu S. , Ryan Charles J. , Stuyckens Kim , Smith Matthew R. , Saad Fred , Griffin Thomas W. , Park Youn C. , Yu Margaret K. , Vermeulen An , Poggesi Italo , Nandy Partha
Published: April 2023

Supplemental Methods, Table 1 and Figures 1-2. Appendix I: TGI PSA kinetic model, Appendix II: Survival analysis. Supplementary Table 1. Parameter estimates of the final PSA kinetic model. Supplementary Figure 1. Diagnostic plot of the observed and predicted PSA concentrations for the PSA kinetic models. Supplementary Figure 2. Comparison of predicted survival probability based on the final multivariate PSA-survival model to the observed survival probability over time.
Supplementary Figure S2 from HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
Authors: Carson Robbie , Celtikci Basak , Fenning Cathy , Javadi Arman , Crawford Nyree , Perez-Carbonell Lucia , Lawler Mark , Longley Daniel B. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Supplementary Figure S2. Effect of JAK1/JAK2 inhibition alone and in combination with MEK inhibition on survival of BRAFMT colorectal cancer cells
Supplementary table 1, supplementary table 2 from Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care
Authors: El Messaoudi Safia , Mouliere Florent , Du Manoir Stanislas , Bascoul-Mollevi Caroline , Gillet Brigitte , Nouaille Michelle , Fiess Catherine , Crapez Evelyne , Bibeau Frederic , Theillet Charles , Mazard Thibault , Pezet Denis , Mathonnet Muriel , Ychou Marc , Thierry Alain R.
Published: April 2023

supplementary Table 1: detailed data of included patients supplementary table 2: relation of ccfDNA parameters with clinical variables.
Supplementary figure 1A from ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment
Authors: Lamberts Laetitia E. , Menke-van der Houven van Oordt Catharina W. , ter Weele Eva J. , Bensch Frederike , Smeenk Michiel M. , Voortman Johannes , Hoekstra Otto S. , Williams Simon P. , Fine Bernard M. , Maslyar Daniel , de Jong Johan R. , Gietema Jourik A. , Schröder Carolien P. , Bongaerts Alphons H.H. , Lub-de Hooge Marjolijn N. , Verheul Henk M.W. , Sanabria Bohorquez Sandra M. , Glaudemans Andor W.J.M. , de Vries Elisabeth G.E.
Published: April 2023

A. PET uptake in the circulation per cohort, as determined by region of interest drawn in left ventricle; cohort 1 (in blue) contained 2 patients (0 mg additional MMOT0530A), cohort 2 (in green) contained 9 patients (10 mg additional MMOT0530A). On X axis the different PET moments: 2, 4 and 7 days post injection. On the Y axis the mean SUVmax per cohort.
Supplementary Table S1 from CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer—Where Did It Start and Where Are We Now?
Authors: Gingras Isabelle , Desmedt Christine , Ignatiadis Michail , Sotiriou Christos
Published: April 2023

Summary of the commercially available proliferation-based gene-signatures in breast cancer
Supplementary figure legends from CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells
Authors: Bruns Heiko , Bessell Catherine , Varela Juan Carlos , Haupt Carl , Fang Jerry , Pasemann Shirin , Mackensen Andreas , Oelke Mathias , Schneck Jonathan P. , Schütz Christian
Published: April 2023

Supplementary figure legends
Supplementary Figure S1 from Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
Authors: Sachs Jeffrey R. , Mayawala Kapil , Gadamsetty Satvik , Kang Soonmo Peter , de Alwis Dinesh P.
Published: April 2023

Summary of results from the review of MTDs and approved doses
Supplementary Table 3 from Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer
Authors: Liu Stephen V. , Tsao-Wei Denice D. , Xiong Shigang , Groshen Susan , Dorff Tanya B. , Quinn David I. , Tai Yu-Chong , Engel Juergen , Hawes Debra , Schally Andrew V. , Pinski Jacek K.
Published: April 2023

Supplemental Table 3. Cardiac and Pituitary Analyses. FSH, follicle stimulating hormone; MUGA, multigated acquisition study; TSH, thyroid stimulating hormone.
Supplementary Figure Legends and Tables from A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
Authors: Drilon Alexander , Somwar Romel , Wagner Jacob P. , Vellore Nadeem A. , Eide Christopher A. , Zabriskie Matthew S. , Arcila Maria E. , Hechtman Jaclyn F. , Wang Lu , Smith Roger S. , Kris Mark G. , Riely Gregory J. , Druker Brian J. , O'Hare Thomas , Ladanyi Marc , Davare Monika A.
Published: April 2023

Supplementary Figure Legends and Supplementary Tables. Supplementary Table S1. Detailed clinical and diagnostic summary for a patient with ROS1-rearranged lung adenocarcinoma who developed acquired resistance to crizotinib and responded to cabozantinib. Supplementary Table S2. Next-generation sequencing results reveal a novel acquired ROS1 D2033N mutation in the CD74-ROS1 kinase domain.
Supplemental Figure 5 from iNOS Expression in CD4+ T Cells Limits Treg Induction by Repressing TGFβ1: Combined iNOS Inhibition and Treg Depletion Unmask Endogenous Antitumor Immunity
Authors: Jayaraman Padmini , Alfarano Matthew G. , Svider Peter F. , Parikh Falguni , Lu Geming , Kidwai Sarah , Xiong Huabao , Sikora Andrew G.
Published: April 2023

Supplemental Figure 5. Unfractionated splenocytes derived from WT mice were activated with soluble anti-CD3 +anti-CD28 antibodies in the presence or absence of LNIL. The cells were harvested 5 days after activation and stained for MDSC ( Gr-1+CD11b+), macrophages ( CD11b+F480+) or Dendritic cells ( F480-Cd11C+MHC Class II+) cells and intracellularly stained for TGF-b1. The graph shows the levels of TGF-b ( from both control and LNIL treated cells)expressed as a fold-increase with respect to the control group.
Supplementary Figure 8 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Authors: Nebbioso Angela , Carafa Vincenzo , Conte Mariarosaria , Tambaro Francesco Paolo , Abbondanza Ciro , Martens Joost , Nees Matthias , Benedetti Rosaria , Pallavicini Isabella , Minucci Saverio , Garcia-Manero Guillermo , Iovino Francesco , Lania Gabriella , Ingenito Concetta , Belsito Petrizzi Valeria , Stunnenberg Hendrik G. , Altucci Lucia
Published: April 2023

SAHA effects in normal cells.
Supplementary Figure 2 from Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma
Authors: Otsuka Atsushi , Dreier Jil , Cheng Phil F. , Nägeli Mirjam , Lehmann Holger , Felderer Lea , Frew Ian J. , Matsushita Shigeto , Levesque Mitchell P. , Dummer Reinhard
Published: April 2023

Figure S2: Higher magnification photos of MHC class I expression (A) MHC class I expression on tumor cells after 4 week treatment with Hh inhibitors. Scale bar; 400 µm (upper), 50 µm (lower)
Supplementary Figure 4 from Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation
Authors: Hung Amos C. , Lo Steven , Hou Ming-Feng , Lee Yi-Chen , Tsai Chun-Hao , Chen Yuan-Yin , Liu Wangta , Su Yu-Han , Lo Yi-Hsuan , Wang Chie-Hong , Wu Shiou-Chen , Hsieh Ya-Ching , Hu Stephen Chu-Sung , Tai Ming-Hong , Wang Yun-Ming , Yuan Shyng-Shiou F.
Published: April 2023

Supplementary Figure 4. A, Effect of visfatin on anoikis cell death.
Supplementary figure 3 from Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Authors: Tang Ke-Jing , Constanzo Jerfiz D. , Venkateswaran Niranjan , Melegari Margherita , Ilcheva Mariya , Morales Julio C. , Skoulidis Ferdinandos , Heymach John V. , Boothman David A. , Scaglioni Pier Paolo
Published: April 2023

Supplementary Figure 3. Inhibition of FAK causes upregulation of γ-H2AX.
Supplementary figure 2 from Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Authors: Tang Ke-Jing , Constanzo Jerfiz D. , Venkateswaran Niranjan , Melegari Margherita , Ilcheva Mariya , Morales Julio C. , Skoulidis Ferdinandos , Heymach John V. , Boothman David A. , Scaglioni Pier Paolo
Published: April 2023

Supplementary Figure 2. Suppression of FAK did not affect p-AKT, p-ERK and p-S6.
Supplementary Information from Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Authors: Tang Ke-Jing , Constanzo Jerfiz D. , Venkateswaran Niranjan , Melegari Margherita , Ilcheva Mariya , Morales Julio C. , Skoulidis Ferdinandos , Heymach John V. , Boothman David A. , Scaglioni Pier Paolo
Published: April 2023

Supplementary Materials and Methods
Supplementary Figures from Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors
Authors: Lu Shengjun , Zhang Jinyu , Liu Dai , Li Guangfu , Staveley-O'Carroll Kevin F. , Li Zihai , Wu Jennifer D.
Published: April 2023

Supplementary Figure 1. Basic functional characterization of B10G5 antibody. Supplementary Figure 2. Changes in serum levels of cytokines and chemokines with depletion of lymphocyte subsets during B10G5 therapy. Supplementary Figure 3. Anti-sMIC mAb B10G5 therapy significantly increase homeostatic proliferation of adoptively transferred NK cells. Supplementary Figure 4. B10G5 therapy did not impact CD4 T cell homeostasis but increased T-bet expression. Supplementary Figure S5. Undetectable endogenous SV40TAg epitope I-specific CD8 T cells shown by lack of positive staining by H-2Db-restrcited TAg epitope I-specific tetramer (Db/I-Tetramer). Supplementary Figure 6. Anti-sMIC mAb B10G5 therapy inhibits the growth of transplantable TRAMP-sMICB tumors. Supplementary Figure 7. Anti-sMIC therapy enhanced antigen-specific CD8 T cell responses in the transplantable TRAMP-C2-sMICB-OVA tumor model. Supplementary Figure 8. Therapeutic effect of B10G5 against well-differentiated TRAMP/MICB tumors. Supplementary Figure S9. Representative flow cytometry analyses demonstrating that depletion of NK cells during B10G5 therapy impairs CD4 T cell Th1 responses.
Supplementary Tables from Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
Authors: Santa-Maria Cesar A. , Blackford Amanda , Nguyen Anne T. , Skaar Todd C. , Philips Santosh , Oesterreich Steffi , Rae James M. , Desta Zeruesenay , Robarge Jason , Henry Norah Lynn , Storniolo Anna M. , Hayes Daniel F. , Blumenthal Roger S. , Ouyang Pamela , Post Wendy S. , Flockhart David A. , Stearns Vered
Published: April 2023

Supplementary table 1. Findings of multivariable linear regressions analyzing genetic associations between candidate gene SNPs and lipid profiles in exemestane-treated participants complementary to statistically significant findings in letrozole-treated participants. Supplementary table 2. Findings of multivariable linear regressions analyzing genetic associations between candidate gene SNPs and lipid profiles in only Caucasian women taking both letrozole and exemestane complementary to statistically significant findings in letrozole-treated participants. *new significant finding (in letrozole only), and corresponding data for exemestane (additive rs1062033 and dominant rs1062033 models were not included due to number of homozygotes <5) Supplementary table 3. Significant findings of multivariable linear regressions analyzing genetic associations between candidate gene SNPs and lipid profiles without adjusting for changes in plasma estradiol concentrations.
Supplementary Figures S1-S6 from Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas
Authors: Lee Misu , Wiedemann Tobias , Gross Claudia , Leinhäuser Ines , Roncaroli Federico , Braren Rickmer , Pellegata Natalia S.
Published: April 2023

Supplementary Figures S1-S6. Supplementary Fig S1. Histological and immunohistological analysis of a pituitary adenoma from a MENX and 3D organotypic cultures obtained from a rat; Supplementary Fig S2. (A) Expression of phosphorylated (p) AKT and P-S6 proteins in pituitary tumors of MENX mutant rats. (B)Principle component analysis (PCA) of MALDI Imaging proteomics data; Supplementary Fig S3. Hematoxylin and eosin (H&E) staining of MENX-associated pituitary tumors; Supplementary Fig S4. Scatter plot images of gene expression profiling done on NVPBEZ235-treated (Group 1) 3D rat primary NFPA cultures versus DMSO-treated cultures (Control Group); Supplementary Fig S5. Co-IF of BD-1 (green) and LH (red) in human normal pituitary; Supplementary Fig S6. Knock-down of Defb1 in BON1 and QGHP1 cells.
Supplementary Figure 1a from Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
Authors: Santa-Maria Cesar A. , Blackford Amanda , Nguyen Anne T. , Skaar Todd C. , Philips Santosh , Oesterreich Steffi , Rae James M. , Desta Zeruesenay , Robarge Jason , Henry Norah Lynn , Storniolo Anna M. , Hayes Daniel F. , Blumenthal Roger S. , Ouyang Pamela , Post Wendy S. , Flockhart David A. , Stearns Vered
Published: April 2023

Supplementary Figure 1a. Manhattan plots demonstrating associations between variants in the CYP19A1 gene and absolute changes HDL-C using dominant (A) and additive (B) in letrozole treated participants taking lipid lowering medication.
Supplementary figures from Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer
Authors: Liu Yi-Rong , Jiang Yi-Zhou , Xu Xiao-En , Hu Xin , Yu Ke-Da , Shao Zhi-Ming
Published: April 2023

Supplementary Figure 1. Kaplan-Meier estimates of recurrence-free survival (RFS) according to the expression of every ten mRNA/lncRNA incorporated in the integrated signature in the training set (n=165). RNA expression level was coded as high or low according to the median expression level. Supplementary Figure 2. Validation of the expression of each mRNA/lncRNA incorporated in the integrated signature in the 33 paired tumor and normal breast tissues from the training set using quantitative real-time polymerase chain reaction (qRT-PCR). Supplementary Figure 3. Flowchart of the study design, patient selection and analytical strategy. Supplementary Figure 4. Details of the filtration procedures. For lncRNAs, either lncRNAs with fold change >1.5 and P<0.05 in survival analysis or fold change >2 and P<0.1 were included. Supplementary Figure 5. Down regulations of the HIST2H2BC and SNRPEP4 enhanced apoptosis induced by paclitaxel. Supplementary Figure 6. Flow cytometric analyses of cell cycle distribution in control and siRNA knockdown breast cancer cells.
Table S5 from SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Authors: Hidalgo Manuel , Plaza Carlos , Musteanu Monica , Illei Peter , Brachmann Carrie B. , Heise Carla , Pierce Daniel , Lopez-Casas Pedro P. , Menendez Camino , Tabernero Josep , Romano Alfredo , Wei Xinyu , Lopez-Rios Fernando , Von Hoff Daniel D.
Published: April 2023

Table S5. Changes in Plasma SPARC From Baseline to Cycles 2 and 4
Supplementary Table 2 from Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma
Authors: Kephart Julie J.G. , Tiller Rosanne G.J. , Crose Lisa E.S. , Slemmons Katherine K. , Chen Po-Han , Hinson Ashley R. , Bentley Rex C. , Chi Jen-Tsan Ashley , Linardic Corinne M.
Published: April 2023

Supplementary Table 2. The induced and repressed probesets and gene names that have been selected by SAM.
Figure S1 from SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Authors: Hidalgo Manuel , Plaza Carlos , Musteanu Monica , Illei Peter , Brachmann Carrie B. , Heise Carla , Pierce Daniel , Lopez-Casas Pedro P. , Menendez Camino , Tabernero Josep , Romano Alfredo , Wei Xinyu , Lopez-Rios Fernando , Von Hoff Daniel D.
Published: April 2023

Figure S1 . Representative SPARC staining. (A) Representative SPARC staining in stroma. (B) Representative SPARC staining in tumor epithelia.
Supplementary Figure 1 from Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma
Authors: Kephart Julie J.G. , Tiller Rosanne G.J. , Crose Lisa E.S. , Slemmons Katherine K. , Chen Po-Han , Hinson Ashley R. , Bentley Rex C. , Chi Jen-Tsan Ashley , Linardic Corinne M.
Published: April 2023

Supplementary Figure 1. Doxycycline-inducible SFRP3 shRNA inhibit cell growth.
Supplementary Tables & Figures from Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity
Authors: Dorling Leila , Barnett Gillian C. , Michailidou Kyriaki , Coles Charlotte E. , Burnet Neil G. , Yarnold John , Elliott Rebecca M. , Dunning Alison M. , Pharoah Paul D.P. , West Catharine M.
Published: April 2023

Supplementary Table 1: The late toxicity endpoints recorded in the RAPPER breast cohorts Supplementary Table 2: RTOG acute toxicity grades definition Supplementary Table 3: Statistically significant non-genetic factors for acute and five-year toxicity Supplementary Table 4: Results from residual analyses of the effect of individual risk variants on acute and two-year toxicity Supplementary Table 5: Results from residual analyses of individual risk variants and five-year toxicity Supplementary Figures 1-9: QQ plots comparing expected and observed p-values for the associations between individual breast cancer risk SNPs and each toxicity endpoint Supplementary Figures 10-17: Scatter plots of individual breast cancer risk variants comparing their effect on breast cancer risk with their effects on each toxicity endpoint
Supplementary Figure S1 from Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Authors: Brown Jennifer R. , Davids Matthew S. , Rodon Jordi , Abrisqueta Pau , Kasar Siddha N. , Lager Joanne , Jiang Jason , Egile Coumaran , Awan Farrukh T.
Published: April 2023

Figure S1. Individual and mean AUC0-24 ({plus minus} standard deviation) in patients with solid tumors (37) (n = 14) or lymphoma (n = 9) on cycle 1, day 28 after treatment with pilaralisib (SAR245408) 600 mg capsules once daily.
Supplementary Table 1 from HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
Authors: Napolitano Andrea , Antoine Daniel J. , Pellegrini Laura , Baumann Francine , Pagano Ian , Pastorino Sandra , Goparaju Chandra M. , Prokrym Kirill , Canino Claudia , Pass Harvey I. , Carbone Michele , Yang Haining
Published: April 2023

Full demographic characterization of individuals involved in the study.
Supplementary Figure 1 from HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
Authors: Napolitano Andrea , Antoine Daniel J. , Pellegrini Laura , Baumann Francine , Pagano Ian , Pastorino Sandra , Goparaju Chandra M. , Prokrym Kirill , Canino Claudia , Pass Harvey I. , Carbone Michele , Yang Haining
Published: April 2023

Comparison of mesothelin and HMGB1 levels using respectively different reagents or techniques
Video 4 from In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
Authors: Lehmann Steffi , Perera Ramanil , Grimm Hans-Peter , Sam Johannes , Colombetti Sara , Fauti Tanja , Fahrni Linda , Schaller Teilo , Freimoser-Grundschober Anne , Zielonka Jörg , Stoma Szymon , Rudin Markus , Klein Christian , Umana Pablo , Gerdes Christian , Bacac Marina
Published: April 2023

Ex vivo analysis of the CEA TCB (magenta) mediated cross-linking of CFSE labeled T-cells (green) to tumor cells. 3D reconstructions of confocal z-stacks acquired on tumor sections obtained from huPBMC (CFSE labeled T-cells)/LS174T RFP co-grafts, 24 h after intravenous A647 labeled CEA TCB injections are shown. Bar, 10 ÃŽÂ¼m. Cell nuclei (DAPI) are shown in blue.
Supplementary 2 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Authors: Yu Shang-Fan , Zheng Bing , Go MaryAnn , Lau Jeff , Spencer Susan , Raab Helga , Soriano Robert , Jhunjhunwala Suchit , Cohen Robert , Caruso Michele , Polakis Paul , Flygare John , Polson Andrew G.
Published: April 2023

Supplementary 2. In vivo efficacy of anti-CD22-vc-MMAE and anti-CD22-SPDB-DM4
Supplementary 1 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Authors: Yu Shang-Fan , Zheng Bing , Go MaryAnn , Lau Jeff , Spencer Susan , Raab Helga , Soriano Robert , Jhunjhunwala Suchit , Cohen Robert , Caruso Michele , Polakis Paul , Flygare John , Polson Andrew G.
Published: April 2023

Supplementary 1. In vivo efficacy of anti-CD22-vc-MMAE
Supplementary Highlighted Methods from Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver
Authors: Emmanuel Catherine , Chiew Yoke-Eng , George Joshy , Etemadmoghadam Dariush , Anglesio Michael S. , Sharma Raghwa , Russell Peter , Kennedy Catherine , Fereday Sian , Hung Jillian , Galletta Laura , Hogg Russell , Wain Gerard V. , Brand Alison , Balleine Rosemary , MacConaill Laura , Palescandolo Emanuele , Hunter Sally M. , Campbell Ian , Dobrovic Alexander , Wong Stephen Q. , Do Hongdo , Clarke Christine L. , Harnett Paul R. , Bowtell David D.L. , deFazio Anna
Published: April 2023

Supplementary Highlighted Methods. This document contains the revised supplementary methods and results with changes highlighted
Supplementary Tables S1-2, Figure 1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Authors: Patnaik Amita , Kang S. Peter , Rasco Drew , Papadopoulos Kyriakos P. , Elassaiss-Schaap Jeroen , Beeram Muralidhar , Drengler Ronald , Chen Cong , Smith Lon , Espino Guillermo , Gergich Kevin , Delgado Liliana , Daud Adil , Lindia Jill A. , Li Xiaoyun Nicole , Pierce Robert H. , Yearley Jennifer H. , Wu Dianna , Laterza Omar , Lehnert Manfred , Iannone Robert , Tolcher Anthony W.
Published: April 2023

Supplementary Tables S1-2, Figure 1. Supplementary Table S1. Matrix view of Part A-2 dose titration and PK sampling scheme. Supplementary Table S2. Efficacy outcomes by investigator review per RECIST v1.1. Supplementary Figure 1. Seventeen patients were tested with IFN-γ ELISPOT assay.
Supplementary materials and methods, supplement figure S1: to S12, and supplement table S1 from Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression
Authors: Hsu Chiun , Lin Liang-In , Cheng Yu-Che , Feng Zi-Rui , Shao Yu-Yun , Cheng Ann-Lii , Ou Da-Liang
Published: April 2023

Supplement Figure S1: The six E2Fs binding sites in cyclin E1 promoter; Supplement Figure S2: Suppression of cyclin E1 by sorafenib correlated with sorafenib sensitivity; Supplement Figure S3: Effects of sorafenib and the Raf kinase inhibitor on cyclin E1 suppression in HCC cells; Supplement Figure S4: Knockdown of cyclin E1, but not cyclin E2, significantly increased the sensitivity to sorafenib in HCC cells; Supplement Figure S5: Effects of cyclin E1 or Mcl-1 inhibition on sorafenib-induced apoptosis; Supplement Figure S6: Effects of E2F1 suppression on cyclin E1 expression; Supplement Figure S7: Effects of flavopiridol on cyclin E1 and Rb protein levels in HCC cells; Supplement Figure S8: Synergistic anti-tumor activity between sorafenib and the CDK inhibitor flavopiridol; Supplement Figure S9: Differential effect between sorafenib and the CDK inhibitor flavopiridol on cell-cycle progression of HCC cells; Supplement Figure S10: The apoptosis-related proteins measured by the Human Apoptosis Array kit; Supplement Figure S11: In vivo evidence of toxicity between sorafenib and flavopiridol in HCC cells; Supplement Figure S12: Flavopiridol enhanced the anti-tumor efficacy of sorafenib in vivo; and Supplement Table S1: Primers list and Supplementary materials and methods.
Supplementary Tables from Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection
Authors: Wu Ting-Jung , Chang Shih-Shin , Li Chia-Wei , Hsu Yi-Hsin , Chen Tse-Ching , Lee Wei-Chen , Yeh Chau-Ting , Hung Mien-Chie
Published: April 2023

Supplementary Table S1. List of antibodies used for the immunoblotting, immunofluorescence, and immunohistochemistry. Supplementary Table S2. List of inhibitors used in this study with stock concentration and dilution. Supplementary Table S3. List of forward and reverse primers used for the indicated assays. Supplementary Table S4. The demographic data of 232 HCC patients who underwent curative resection. Supplementary Table S5. The severity of hepatitis according to ISHAK score in patients with viral hepatitis. Supplementary Table S5. Comparison of early and late HCC recurrence by the ISHAK score parameters. Supplementary Table S6. The rate of HCC recurrence and extra-hepatic metastasis in patients with severe or mild/none hepatitis. Supplementary Table S7. Comparison of early and late HCC recurrence by the ISHAK score parameters. Supplementary Table S8. Cytokine antibody array analysis of 8 paired normal and tumor tissues from patients according to the severity of hepatitis. Supplementary Table S9. Correlation between the severity of hepatitis and the expression level of p65, Snail and E-cadherin.
Supplementary Figure S1-8 from Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation—An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302
Authors: Saggar Jasdeep K. , Tannock Ian F.
Published: April 2023

Supplementary Figure S1-8. Figure S1. Reoxygenation and Repopulation at 48 hours in MCF-7 tumors. Figure S2. Reoxygenation and Repopulation at 72 hours in MCF-7 tumors. Figure S3. Reoxygenation and Repopulation at 96 hours in MCF-7 tumors. Figure S4. Reoxygenation and Repopulation at 120 hours in MCF-7 tumors. Figure S5. Reoxygenation and Repopulation at 48 hours in PC-3 tumors. Figure S6. Reoxygenation and Repopulation at 72 hours in PC-3 tumors. Figure S7. Reoxygenation and Repopulation at 96 hours in PC-3 tumors. Figure S8. Reoxygenation and Repopulation at 120 hours in PC-3 tumors.
Supplementary Figure Legends from Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation—An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302
Authors: Saggar Jasdeep K. , Tannock Ian F.
Published: April 2023

supplementary figure legends
Supplemental Figure 1 from PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Authors: Stern Howard M. , Gardner Humphrey , Burzykowski Tomasz , Elatre Wafaa , O'Brien Carol , Lackner Mark R. , Pestano Gary A. , Santiago Angela , Villalobos Ivonne , Eiermann Wolfgang , Pienkowski Tadeusz , Martin Miguel , Robert Nicholas , Crown John , Nuciforo Paolo , Bee Valerie , Mackey John , Slamon Dennis J. , Press Michael F.
Published: April 2023

Supplemental Figure 1. Clinical trial schemata. Diagrammatic representation of the BCIRG 005 (A) and BCIRG 006 (B) adjuvant breast cancer clinical trials
Supplement Text AND ALL Supplement Figures from PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Authors: Stern Howard M. , Gardner Humphrey , Burzykowski Tomasz , Elatre Wafaa , O'Brien Carol , Lackner Mark R. , Pestano Gary A. , Santiago Angela , Villalobos Ivonne , Eiermann Wolfgang , Pienkowski Tadeusz , Martin Miguel , Robert Nicholas , Crown John , Nuciforo Paolo , Bee Valerie , Mackey John , Slamon Dennis J. , Press Michael F.
Published: April 2023

Supplement Text AND ALL Supplement Figures
Supplementary table 2 from Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer
Authors: Banerjee Sulagna , Modi Shrey , McGinn Olivia , Zhao Xianda , Dudeja Vikas , Ramakrishnan Sundaram , Saluja Ashok K.
Published: April 2023

IC50 of mouse CAFs and PDACs after 48h treatment with triptolide in vitro.
Supplemental Figure 3 from A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma
Authors: Martuscello Regina T. , Vedam-Mai Vinata , McCarthy David J. , Schmoll Michael E. , Jundi Musa A. , Louviere Christopher D. , Griffith Benjamin G. , Skinner Colby L. , Suslov Oleg , Deleyrolle Loic P. , Reynolds Brent A.
Published: April 2023

The sHFLC diet maintains animal health in second patient derived glioblastoma stem cell line.
Supplemental Figure 2 from A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma
Authors: Martuscello Regina T. , Vedam-Mai Vinata , McCarthy David J. , Schmoll Michael E. , Jundi Musa A. , Louviere Christopher D. , Griffith Benjamin G. , Skinner Colby L. , Suslov Oleg , Deleyrolle Loic P. , Reynolds Brent A.
Published: April 2023

Glucose restriction coupled with ketone body treatment further slows proliferation of multiple patient-derived glioblastoma stem cell lines
Supplementary figure 3 from Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer
Authors: Banerjee Sulagna , Modi Shrey , McGinn Olivia , Zhao Xianda , Dudeja Vikas , Ramakrishnan Sundaram , Saluja Ashok K.
Published: April 2023

Gene expression of collagen stabilization genes
Supplementary figure 1 from Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer
Authors: Banerjee Sulagna , Modi Shrey , McGinn Olivia , Zhao Xianda , Dudeja Vikas , Ramakrishnan Sundaram , Saluja Ashok K.
Published: April 2023

Gene expression in normal ductal cells and cancer cells
Supplemental Table 3 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
Authors: Boyiadzis Michael , Arora Mukta , Klein John P. , Hassebroek Anna , Hemmer Michael , Urbano-Ispizua Alvaro , Antin Joseph H. , Bolwell Brian J. , Cahn Jean-Yves Y. , Cairo Mitchell S. , Cutler Corey S. , Flowers Mary E. , Gale Robert P. , Herzig Roger , Isola Luis M. , Jacobsohn David A. , Jagasia Madan H. , Klumpp Thomas R. , Lee Stephanie J. , Petersdorf Effie W. , Santarone Stella , Spellman Stephen R. , Schouten Harry C. , Verdonck Leo F. , Wingard John R. , Weisdorf Daniel J. , Horowitz Mary M. , Pavletic Steven Z.
Published: April 2023

Supplemental Table 3. Multivariate analysis showing impact of cGVHD characteristics on treatment related mortality, disease free survival and overall survival in patients with CML who developed cGVHD
Supplementary Table 1 from Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Authors: Ziemke Elizabeth K. , Dosch Joseph S. , Maust Joel D. , Shettigar Amrith , Sen Ananda , Welling Theodore H. , Hardiman Karin M. , Sebolt-Leopold Judith S.
Published: April 2023

Clinical and Pathological Features of 18 CRC PDX Models Established from Patients Undergoing Surgical Resection or Hepatic Metastasectomy at the University of Michigan
Supplementary Figure Legend from Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Authors: Ziemke Elizabeth K. , Dosch Joseph S. , Maust Joel D. , Shettigar Amrith , Sen Ananda , Welling Theodore H. , Hardiman Karin M. , Sebolt-Leopold Judith S.
Published: April 2023

Supplementary Figure Legend
Supplementary Figure 6 from Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Authors: Ziemke Elizabeth K. , Dosch Joseph S. , Maust Joel D. , Shettigar Amrith , Sen Ananda , Welling Theodore H. , Hardiman Karin M. , Sebolt-Leopold Judith S.
Published: April 2023

Total Rb and ERK Expression in Treated and Control CRM 13-180 Tumors. Expression levels of total Rb and total ERK in CRM 13-180 tumors after treatment by oral garage with vehicle, trametinib, palbociclib, or the combination of these two agents.
Supplemental Table 4-6 from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Authors: Beuselinck Benoit , Job Sylvie , Becht Etienne , Karadimou Alexandra , Verkarre Virginie , Couchy Gabrielle , Giraldo Nicolas , Rioux-Leclercq Nathalie , Molinié Vincent , Sibony Mathilde , Elaidi Reza , Teghom Corinne , Patard Jean-Jacques , Méjean Arnaud , Fridman Wolf Herman , Sautès-Fridman Catherine , de Reyniès Aurélien , Oudard Stéphane , Zucman-Rossi Jessica
Published: April 2023

Supplemental Table 4-6. Table S4: Detail for each sample of the PBRM1 and VHL-mutation status. NA stands for Not Available. Table S5: For each data type, clinical, transcriptome, methylome or SNP array, sensitity and specificity of the two predictors: PD vs (PR+SD) and PR vs (PD+SD) in the training and validation sets. The 'N()' columns indicate the numbers of each responder type. Table S6: List of the 27 genes firstly used by the classifier to predict the subtypes ccrcc2, ccrcc3 and the joint subtype ccrcc14 and list of the 8 genes used by the second classifier to assign the ccrcc14 samples to the two subtypes ccrcc1 and ccrcc4.
Supplementary Figure 3 from Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Authors: Ziemke Elizabeth K. , Dosch Joseph S. , Maust Joel D. , Shettigar Amrith , Sen Ananda , Welling Theodore H. , Hardiman Karin M. , Sebolt-Leopold Judith S.
Published: April 2023

Total RB Expression in CRC PDX Models. IHC staining for total RB expression in five CRC PDX models and matched normal colon mucosa.